Abstract P2-03-07: Neoadjuvant (Z)-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor 2 (HER2)- Breast Cancer (BC): Evaluation of Quality of Life (QOL) measures in the EVANGELINE Study
Sarah Premji, Matthew P. Goetz(Mayo Clinic), Pooja Advani(Jacksonville College), Amy C. Degnim(Mayo Clinic in Arizona), Daniel Flora(St. Elizabeth Healthcare), Felipe Batalini(Beth Israel Deaconess Medical Center), Patricia A. Cronin(Mayo Clinic in Arizona), Joel M. Reid(Children's Hospital of Philadelphia), Jason M. Jones, Tufia C. Haddad(Mayo Clinic), Judy C. Boughey(Mayo Clinic in Arizona), John R. Hawse(Mayo Clinic in Arizona), Swaathi Jayaraman(Johns Hopkins University), Harjinder Singh(Riddet Institute), Katie N. Hunt(Mayo Clinic), Nusayba A. Bagegni(Washington University in St. Louis), Amye J. Tevaarwerk, Roberto A. Leon‐Ferre(Mayo Clinic), Lida A. Mina(Mayo Clinic in Arizona), Mara A. Piltin(Mayo Clinic), Vera J. Suman(Mayo Clinic in Arizona), James N. Ingle(Mayo Clinic), Karthik V. Giridhar(WinnMed), Steven C. Quay(Aptevo Therapeutics (United states)), Arezoo Mirad, Matthew J. Schellenberg(Mayo Clinic)
Cited by 0
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
|Clinical Cancer Research|2013|744